NEW DELHI, India, (April 18, 2024) – Dishman Carbogen Amcis Ltd received the Choose France-Best Indian Investment in France award by the Indo French Chamber of Commerce & Industry in partnership with Business France India, at the sixth flagship event of the Indo-French Business Awards (IFBA) and Grand Prix VIE, in New Delhi. His Excellency Mr. Thierry Mathou, Ambassador of France presented the award which recognises Dishman’s investment in a new state-of-the-art facility in Saint Beauzire, France, and the increase in Human Capital over the last few years.

Giving a detailed overview of the company's facility in Saint Beauzire and future business plans, Mr. Harshil Dalal, Group CFO - Dishman Group, stated:

“We thank the Indo French Chamber of Commerce and Industry for this wonderful recognition of our efforts to make France our destination of choice to do business."

Dishman Carbogen Amcis Ltd stands as a beacon of innovation and progress in the healthcare industry, transcending borders with our multi-site transcontinental presence. With 11 manufacturing sites and 6 sales offices spread across 6 countries, and subsidiaries in key regions like Switzerland, France, Netherlands, UK, and China, we're poised to deliver comprehensive healthcare solutions like never before.

Our journey in France epitomizes our commitment to growth and excellence. In 2012, we acquired a small but promising company, igniting a transformative journey in the realm of Sterile Investigational Medicinal Products (IMPS). Specializing in complex compounds, this facility became a nucleus for innovation, crafting aseptic drug products for preclinical and clinical batches in various forms.

Fast forward to 2023, a milestone year as we inaugurated our state-of-the-art facility in Saint Beauzire. With a Euro 58 million investment, this cutting-edge 9500 m2 establishment symbolizes our dedication to pushing boundaries. Operational since October 2023, it hosts over 100 skilled professionals, a testament to our commitment to job creation and skill development.

Our growth trajectory is not just about numbers; it's about impact. From a modest headcount of 34 in 2018-19, we've surged to 120 by March 2024, with sights set on reaching 200 by March 2028. This expansion isn't just about revenue; it's about societal contribution. From Euro 5 million annually to a projected Euro 40 million, our growth isn't just corporate—it's communal.

Beyond financial gains, our France site embodies potential. It's a gateway to new markets, a hub for R&D, and a catalyst for groundbreaking therapies like anti-cancer drugs. As we expand, so does our organizational backbone, with 70 new positions created, heralding a future brimming with opportunities.

Reflecting on our journey, we've come a long way from our humble beginnings. Yet, amidst our growth, the most profound transformation is the confidence we hold in the future—a future shaped by relentless innovation, unwavering dedication, and boundless potential."

Gujarat, India - After a successful on-site inspection, Ahmedabad-based Dishman Carbogen Amcis Ltd (DCAL), receives the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) certification.

DCAL’s drug substances manufacturing facility located in Bavla, underwent an inspection by the Japanese Health Authority. We are glad to announce that the inspection ended satisfactorily, and no major or critical observations were reported. As a result, PMDA recently awarded the company with the certification of GMP compliance. We are proud of this achievement which is an acknowledgement of our efforts toward maintaining current Good Manufacturing Practices (cGMPs). This certification reaffirms our commitment to improving the health of people all over the world.

We take this opportunity to heartily congratulate our teams and laud their sincerity and dedication that led to this positive outcome.

Speaking about the PMDA certification, here is what our COO, Mr. Paolo Armanino, said: “First of all, we would like to thank PMDA for their time and invaluable feedback. We feel proud to continue to be approved by the Japanese Authority. I would also like to extend my heartfelt congratulations to all the team who made this remarkable achievement possible.

We maintain strategic ties with our Japanese customers, and we recognize the company's responsibility to work closely together to improve patient health and safety. Dishman Carbogen Amcis Ltd supplies several critical drugs to the Japanese market, and we see several significant and positive developments in our business in the upcoming years.

Going forward, we aim to further expand our services and products portfolio in Japan to fulfil the customer’s needs. In order to closely engage with the demands and requirements of the Japanese market, we are thrilled to be visiting Tokyo in a few weeks for CPHI Japan, and look forward to meeting our existing and prospective valuable customers and partners.

Ahmedabad, India (December 9th, 2021) — Dishman Carbogen Amcis Ltd, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new Clinical Research Study which shows that oral 25-Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing blood lymphocyte percentages. The research was supervised by Tehran University of Medical Sciences and Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis Ltd’s wholly owned subsidiary CARBOGEN AMCIS B.V.

Dishman Carbogen Amcis Ltd (DCAL) is a leading global manufacturer of vitamin D plus its analogs and related APIs with over 70 years of experience in the field. DCAL partnered with Dr. Michael Holick, MD, PhD, professor of medicine, physiology and biophysics and molecular medicine at Boston University School of Medicine and its team for the Clinical Research Study to be run by the Tehran University of Medical Sciences on treatment with 25-Hydroxyvitamin D3 (Calcifediol) of hospitalized patients with COVID-19.

The study showed that patients receiving the 25-hydroxy metabolite had, in comparison to those receiving a placebo, a demonstrably more favorable development of their immunological defense against COVID-19. Thus, dosing the metabolite significantly increased the blood levels as well as the comparative percentage of lymphocytes in blood, i.e. a reduced Blood Neutrophil-to-Lymphocyte Ratio.

“A person’s vitamin D status is defined as the person’s blood level of the vitamin’s 25-hydroxy metabolite (Calcifediol), i.e. the vitamin’s natural form in circulation which the body can quickly access and finally activate. Therefore, Dishman Carbogen Amcis Ltd has for years studied the effects of dosing either the vitamin and/or the metabolite. Said Dr. Scott Miller, Sr. Scientific Advisor at DCAL, “Our support of this study of Calcifediol in the context of COVID-19 was motivated by the fact that the blood level of the metabolite can be increased more rapidly and more distinctly, if supplemented directly.”

To support the Clinical Research Study CARBOGEN AMCIS B.V. (Netherlands) provided the Active Pharmaceutical Ingredient (Calcifediol) and the capsules and placebo were made at Dishman Carbogen Amcis Ltd’s plant in Bavla, India, specifically for this study.

“There are several studies that have reported that a good vitamin D status i.e. a healthy blood level of 25-hydroxyvitamin D, can not only dramatically reduce the risk of being infected by this deadly virus but also a higher vitamin D status reduced risk for serious symptoms and death caused by the virus.” Commented Dr. Michael Holick. “This controlled study similar to the one conducted in Spain recently ^[1] demonstrate that the rapid improvement in vitamin D status can improve positive outcomes for patients infected with COVID 19.”

“The COVID-19 pandemic hitting the world in early 2020 resulted in unprecedented global focus of R&D efforts and of solidarity in coping with the sudden and unexpected high need for intensive care beds, which didn’t hit all countries to the same degree.” Said Arpit Vyas, Global Managing Director of Dishman Carbogen Amcis Ltd: “It is important for us to play a role in this new challenge, not only for our corporate interests but to contribute to the possible future of the fight against COVID-19. Therefore, to follow up with this Clinical Research Study, Dishman Carbogen Amcis Ltd is currently conducting a second round of study in a larger scale in India.”

For more information about the study supported by Dishman Carbogen Amcis Ltd:
https://www.sciencedirect.com/science/article/pii/S1530891X21012593

^[1] “Effect of Calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”
https://www.sciencedirect.com/science/article/pii/S0960076020302764

****

Dishman Carbogen Amcis Ltd (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.

CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development, allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Carbogen Amcis Ltd., Ahmedabad, India.

OTHER NEWS